Venous thrombosis recurrence risk according to warfarin versus direct oral anticoagulants for the secondary prevention of venous thrombosis

BACKGROUND: Venous thromboembolism (VTE) affects nearly 1 million Americans annually, and many benefit from continued anticoagulation after the initial 3‐ to 6‐month treatment period (secondary prevention). OBJECTIVES: To determine whether warfarin, apixaban, or rivaroxaban is associated with reduce...

Descripción completa

Detalles Bibliográficos
Autores principales: Zakai, Neil A., Walker, Rob F., MacLehose, Richard F., Koh, Insu, Alonso, Alvaro, Lutsey, Pamela L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371351/
https://www.ncbi.nlm.nih.gov/pubmed/34430789
http://dx.doi.org/10.1002/rth2.12575

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371351/
https://www.ncbi.nlm.nih.gov/pubmed/34430789
http://dx.doi.org/10.1002/rth2.12575

Ejemplares similares